Barclays set a €85.00 ($98.84) target price on Bayer (FRA:BAYN) in a research report released on Wednesday morning. The brokerage currently has a buy rating on the healthcare company’s stock.
BAYN has been the subject of several other reports. UBS Group set a €110.00 ($127.91) price objective on shares of Bayer and gave the company a buy rating in a research note on Monday, February 4th. Commerzbank set a €99.00 ($115.12) price target on shares of Bayer and gave the company a buy rating in a research report on Tuesday, November 27th. DZ Bank reiterated a buy rating on shares of Bayer in a research report on Monday, March 11th. Goldman Sachs Group set a €78.00 ($90.70) price target on shares of Bayer and gave the company a buy rating in a research report on Tuesday, November 20th. Finally, Baader Bank set a €123.00 ($143.02) price target on shares of Bayer and gave the company a buy rating in a research report on Friday, January 18th. Nine research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of €87.83 ($102.12).
Shares of FRA:BAYN opened at €59.30 ($68.95) on Wednesday. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: Stop Order Uses For Individual Investors
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.